| Dr Steven L Kidd, MD | |
|
101 Willmar Ave Sw, Willmar, MN 56201 | |
| (320) 231-5000 | |
| (320) 231-5067 |
| Full Name | Dr Steven L Kidd |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 41 Years |
| Location | 101 Willmar Ave Sw, Willmar, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700852589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 39103 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Avera Granite Falls | Granite falls, MN | Hospital |
| Avera Tyler Hospital | Tyler, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Avera Granite Falls | 1456784560 | 13 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Avera Marshall |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568401016 PECOS PAC ID: 5799695227 Enrollment ID: O20031106000219 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Avera Marshall |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1568401016 PECOS PAC ID: 5799695227 Enrollment ID: O20091209000435 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Rural Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215317375 PECOS PAC ID: 3476447541 Enrollment ID: O20150710000034 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Avera Granite Falls |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700429610 PECOS PAC ID: 1456784560 Enrollment ID: O20191204000103 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Entity Name | Avera Granite Falls |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700429644 PECOS PAC ID: 1456784560 Enrollment ID: O20200106000646 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven L Kidd, MD 101 Willmar Ave Sw, Willmar, MN 56201 Ph: (320) 231-5000 | Dr Steven L Kidd, MD 101 Willmar Ave Sw, Willmar, MN 56201 Ph: (320) 231-5000 |
News Archive
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Healthy adults with higher levels of phosphate in the blood are more likely to have increased levels of calcium in the coronary arteries-a key indicator of atherosclerosis and future cardiovascular disease risk, reports a study in the February 2009 issue of the Journal of the American Society of Nephrology (JASN).
Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 1 days ago
Dr. Robert A Kruger, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-231-5000 Fax: 320-231-5067 | |
Dr. Tyler Goettl, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-231-5000 | |
Dr. Thomas H Lange, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-231-5000 Fax: 320-231-5067 | |
Dr. Katherine Faith Reigstad, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 Willmar Ave Sw, Acmc-willmar, Willmar, MN 56201 Phone: 320-231-5010 Fax: 320-231-5067 | |
Dr. Steven R Bell, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-231-5000 Fax: 320-231-5067 | |
Dr. Gordon J Bos, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 101 Willmar Ave Sw, Willmar, MN 56201 Phone: 320-231-5000 Fax: 320-231-5067 |